Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 3/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.40 |
| ▸ | PSMB9 | P28065 | 2/20 | 0.39 |
| ▸ | NMT2 | O60551 | 1/20 | 0.38 |
| ▸ | NMT1 | P30419 | 1/20 | 0.38 |
| ▸ | CALCRL | Q16602 | 3/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30138992 | 0.93 | CAPN1 (0.40) | CAPN1OPRM1OPRD1PSMB9DPP4 | |
| SCHEMBL31347336 | 0.92 | CAPN1 (0.42) | CAPN1OPRM1OPRD1PSMB9NMT2 | |
| SCHEMBL30138993 | 0.92 | OPRM1 (0.42) | CAPN1OPRM1OPRD1PSMB9NMT2 | |
| SCHEMBL31031470 | 0.90 | CAPN1 (0.38) | CAPN1OPRM1OPRD1DPP4PREP | |
| SCHEMBL29679564 | 0.89 | OPRM1 (0.42) | CAPN1OPRM1OPRD1PSMB9CALCRL | |
| SCHEMBL31751644 | 0.88 | OPRM1 (0.43) | CAPN1OPRM1OPRD1PSMB9CALCRL | |
| SCHEMBL30028652 | 0.87 | ITGB1 (0.43) | CAPN1OPRM1OPRD1PREPFAP | |
| SCHEMBL29760955 | 0.86 | OPRM1 (0.41) | CAPN1OPRM1OPRD1PSMB9CALCRL | |
| SCHEMBL30467091 | 0.86 | OPRM1 (0.43) | CAPN1OPRM1OPRD1PSMB9CALCRL | |
| SCHEMBL31751216 | 0.85 | OPRM1 (0.43) | CAPN1OPRM1OPRD1PSMB9CALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264785-A1 | CHEMICALLY MODIFIED PEPTIDES AND USE THEREOF | NEUROCRINE BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | claimed |
| WO-2025087344-A1 | GLP1-R/GIPR DUAL PEPTIDE AGONISTS AND USE THEREOF | BETA PHARMA, INC. (US) | 2025-05-01 | — | — | WO | claimed |
| EP-4267104-A1 | THERAPEUTIC PEPTIDE FORMULATIONS | Eli Lilly and Company (US) | 2023-11-01 | — | — | EP | claimed |
| CN-115181173-A | Preparation method of Tirzepatide | 深圳市健元医药科技有限公司 | 2022-10-14 | — | — | CN | claimed |
| WO-2022140373-A1 | THERAPEUTIC PEPTIDE FORMULATIONS | ELI LILLY AND COMPANY (US) | 2022-06-30 | — | — | WO | claimed |
| WO-2025264809-A1 | CHEMICALLY MODIFIED PEPTIDES AND USE THEREOF | NEUROCRINE BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025264785-A1 | CHEMICALLY MODIFIED PEPTIDES AND USE THEREOF | NEUROCRINE BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025087344-A1 | GLP1-R/GIPR DUAL PEPTIDE AGONISTS AND USE THEREOF | BETA PHARMA, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| EP-4267104-A1 | THERAPEUTIC PEPTIDE FORMULATIONS | Eli Lilly and Company (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-115181173-A | Preparation method of Tirzepatide | 深圳市健元医药科技有限公司 | 2022-10-14 | — | — | CN | disclosed |
| WO-2022140373-A1 | THERAPEUTIC PEPTIDE FORMULATIONS | ELI LILLY AND COMPANY (US) | 2022-06-30 | — | — | WO | disclosed |